Study of DF1001 in Patients with Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

378

Participants

Timeline

Start Date

November 11, 2019

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions
Solid Tumor, Adult
Interventions
DRUG

DF1001

Immunotherapy agent targeting NK cells.

DRUG

Nivolumab

Anti-PD-1 immunotherapy agent

DRUG

Nab paclitaxel

A chemotherapy treatment combining paclitaxel with albumin

DRUG

Sacituzumab Govitecan-hziy

A Trop-2 (Tumor-associated calcium signal transducer 2) directed antibody and topoisomerase inhibitor drug conjugate

Trial Locations (52)

2100

RECRUITING

Rigshospitalet, Copenhagen

2730

RECRUITING

Herlev og Gentofte Hospital, Herlev

4000

RECRUITING

Domaine Universitaire du Sart Tilman; CHU de Liege, Liège

6000

RECRUITING

Grand Hopital de Charleroi, Charleroi

6700

RECRUITING

Centre Hospitalier de l'Ardenne, Arlon

10023

ACTIVE_NOT_RECRUITING

Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center, New York

10461

RECRUITING

Montefiore Einstein Center for Cancer Care, The Bronx

13009

RECRUITING

Institut Paoli Calmettes, Marseille

19104

WITHDRAWN

University of Pennsylvania, Abramson Cancer Center, Philadelphia

21287

RECRUITING

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

31059

RECRUITING

Institut Claudius Regaud, Toulouse

33000

RECRUITING

Groupe Hospitalier Saint Andre, Bordeaux

37232

RECRUITING

Vanderbilt-Ingram Cancer Center, Nashville

43210

RECRUITING

The Ohio State University, Columbus

44106

RECRUITING

University Hospitals Cleveland Medical Center, Cleveland

44805

RECRUITING

ICO - Site Rene Gauducheau, Saint-Herblain

48109

WITHDRAWN

University of Michigan, Ann Arbor

48202

WITHDRAWN

Henry Ford Health System, Detroit

53715

RECRUITING

University of Wisconsin, Madison

59020

RECRUITING

Centre Oscar Lambret, Lille

66205

ACTIVE_NOT_RECRUITING

University of Kansas Medical Center Research Institute, Inc., Westwood

69008

RECRUITING

Centre Leon Berard, Lyon

70112

RECRUITING

Louisiana State University, New Orleans

75005

RECRUITING

Institut Curie, Paris

77030

RECRUITING

MD Anderson Cancer Center, Houston

90033

RECRUITING

University of Southern California, Los Angeles

92123

RECRUITING

Sharp Healthcare, San Diego

92868

RECRUITING

University of California Irvine Medical Center, Irvine

94143

RECRUITING

University of California San Francisco, San Francisco

98405

ACTIVE_NOT_RECRUITING

Multicare Health System Tacoma General Hospital, Tacoma

02903

RECRUITING

Rhode Island Hospital, Providence

Unknown

RECRUITING

Centre Georges-Francois Leclerc, Dijon

RECRUITING

Institut Regional du Cancer de Montepelier, Montpellier

RECRUITING

Groupe Hospitalier Pitie Salpetriere, Paris

RECRUITING

CHU de Rennes Hopital Pontechaillou, Rennes

RECRUITING

Inje University Haeundae Paik Hospital, Busan

RECRUITING

Kosin University Gospel Hospital, Busan

RECRUITING

National Cancer Center, Goyang-si

RECRUITING

Ajou University Hospital, Gyeonggi-do

RECRUITING

CHA Bundang Medical Center, CHA University, Gyeonggi-do

RECRUITING

Seoul National University Bundang Hospital, Seongnam

RECRUITING

Asan Medical Center, Seoul

RECRUITING

Korea University Guro Hospital, Seoul

RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Severance Hospital, Seoul

RECRUITING

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

1081 HV

ACTIVE_NOT_RECRUITING

Amsterdam University Medical Center, Amsterdam

9713 GZ

ACTIVE_NOT_RECRUITING

Universitair Medisch Centrum Groningen, Groningen

6229 HX

ACTIVE_NOT_RECRUITING

Maasticht University Medical Center, Maastricht

6525 EZ

ACTIVE_NOT_RECRUITING

Radboud University Nijmegen, Nijmegen

3015 ZH

ACTIVE_NOT_RECRUITING

Erasmus University Medical Center, Rotterdam

3508 GA

ACTIVE_NOT_RECRUITING

UMC Utrecht, Utrecht

Sponsors
All Listed Sponsors
lead

Dragonfly Therapeutics

INDUSTRY